Other languages Ocumension Therapeutics

Equities

1477

KYG674111011

Delayed Hong Kong S.E. Other stock markets 08:24:24 29/04/2024 am IST			5-day change	1st Jan Change
7.16 ^HKD	+10.66%		+22.60%	+7.19%

15/04	Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug	MT
15/04	Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China	15/04
Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon	08/04
Ocumension Therapeutics Announces Completion of the Phase III Clinical Trial of OT-702 in China	08/04
Ocumension Therapeutics’ Loss for 2023 Narrows; Shares Down 4%	22/03
Ocumension Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Ocumension Therapeutics' Phase 2 Trial for Dry Eye Treatment Meets Clinical Endpoints	14/03
Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202	14/03
Ocumension Therapeutics Receives Approval for Marketing OT-703 in Hong Kong	20/12
Ocumension Therapeutics commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.	13/12
Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing	08/12
Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China	30/11
Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China	22/11
Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023	29/23/29
Ocumension Therapeutics Reports Earnings Results for the Half Year Ended June 30, 2023	24/23/24
Ocumension Therapeutics Announces patient Enrollment Completed in the Real-World Study of OT-502 in Hainan Boao	14/23/14
Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S	20/23/20
Ocumension Therapeutics Completes Patient Enrollment in Globalmulti-Center Phase III Clinical Trial of OT-101	01/23/01
Ocumension Therapeutics Provides Update on OT-1001	26/23/26
Nicox: trésorerie de 21,4 millions d’euros à fin mars, visibilité jusqu’au deuxième trimestre 2024	19/23/19
Nicox Jumps 28% as Chinese Partner Files New Drug Application for Eye Drop	14/23/14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ocumension Therapeutics

Equities

1477

KYG674111011

Other languages

Filters